About 5 results found for searched term "EGFR-IN-57" (0.143 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M45311 | EGFR-IN-57 | EGFR/HER2 |
| EGFR-IN-57 is a potent, orally active EGFR-TK inhibitor with an IC50 value of 0.054 µM. EGFR-IN-57 also inhibits VEGFR-2, CK2α, topoisomerase IIβ, and tubulin polymerization with an IC50 value of 0.087, 0.171, 0.13, and 3.61 µM, respectively. In addition, EGFR-IN-57 induced G2/M and pre-G1 cycle arrest and apoptosis in cancer cells. | ||
| M1749 | Gefitinib | EGFR/HER2 |
| ZD-1839, Iressa | ||
| Gefitinib (ZD1839) is an EGFR tyrosine kinase and Akt phosphorylation inhibitor. Gefitinib significantly down-regulates CD47 expression and increases DC phagocytosis in non-small cell lung cancer cells such as PC9, H1437 and H1573. Gefitinib combined with CD47 antibody can enhance the phagocytosis of macrophages. | ||
| M3026 | Sorafenib (BAY 43-9006) | Raf |
| BAY 43-9006 | ||
| Sorafenib (BAY 43-9006) is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively. Sorafenib is a multikinase inhibitor with IC50 values of 15 nM, 20 nM, 57 nM and 58 nM for VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib is a ferroptosis activator. | ||
| M29606 | NSC689857 | EGFR/HER2 |
| NSC689857 is a potent EGFR and SCFSKP2 inhibitor with an IC50 value of 36 μM for Skp2-Cks1. NSC689857 can inhibit p27 ubiquitylation (IC50=30 μM). NSC689857 has varied activity across cancer types, with more activity against leukemia cell lines than others. | ||
| M42082 | EGFR/BRAFV600E-IN-3 | EGFR/HER2 |
| EGFR/BRAFV600E-IN-3 is a EGFR, BRAFV600E and EGFRT790M inhibitor with IC50 value of 57 nM, 68 nM and 9.70 nM. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
